Actify Neurotherapies
Actify Neurotherapies is a Princeton, NJ-based private clinic network founded in 2011 that delivers IV ketamine infusion therapy across 10 US locations to patients with treatment-resistant depression, PTSD, bipolar depression, OCD, anxiety, and chronic pain.
- Company typePrivate
- Founded2011
- HeadquartersPrinceton, United States
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Actify Neurotherapies does
Actify Neurotherapies, operating under legal entity TC MSO, Inc., is a Princeton, NJ-based private healthcare network founded in 2011 that operates a multi-site clinical service delivering intravenous (IV) ketamine infusion therapy. The company treats six mental health and pain conditions — major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes — positioning ketamine as a rapid-acting alternative for patients who have not responded to traditional daily antidepressant medications.
The business is built around a network of 10 clinic locations spread across the Mid-Atlantic, Northeast, Southeast, West, and South regions of the United States, staffed by approximately 10 board-certified physicians and an operational team of 11–50 employees. Actify has administered 30,000+ cumulative infusions to 2,000+ patients. The underlying technology is a standard IV ketamine infusion protocol; no proprietary compound, device, or digital platform is documented.
Revenue is generated on a per-session basis from patients who pay out of pocket, with intake handled through a direct-to-consumer funnel (free 15-minute phone consultation, website contact form) and supplemented by clinician referrals. Coordination specialists route patients to their preferred clinic location, and treatments are administered in-person. No insurance, enterprise, or payor agreements are documented, and no funding rounds, M&A activity, or parent company relationships have been disclosed.
Actify Neurotherapies firmographics
Firmographics- Name
- Actify Neurotherapies
- Legal name
- TC MSO, Inc.
- Website
- https://actifyneuro.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Actify Neurotherapies is a Princeton, NJ-based private clinic network founded in 2011 that delivers IV ketamine infusion therapy across 10 US locations to patients with treatment-resistant depression, PTSD, bipolar depression, OCD, anxiety, and chronic pain.
- Ownership category
- akta.pro rank
Actify Neurotherapies industry classification
Industry- Product category
- Mental Health Infusion Services
- NAICS
- Outpatient Mental Health and Substance Abuse Centers (62142), Offices of Physicians, Mental Health Specialists (621112)
- SIC
- Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs) (HLAFACAG)
- akta.pro secondary industry
- Pain Medicine (Interventional/Neuropathic Pain) (HLAKAIAM)
Keywords
Where Actify Neurotherapies is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices10 records
Markets served
Actify Neurotherapies business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Ketamine Infusion Treatment Services: Revenue generated from providing intravenous ketamine infusion therapy sessions to patients. Patients pay per treatment session. The company offers treatment for multiple mental health conditions including major depression, PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Treatment session pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Actify Neurotherapies product offering
Product offeringCore offering
Actify Neurotherapies operates a network of 10 ketamine infusion therapy centers across the United States that administer intravenous ketamine treatments to patients with treatment-resistant mental health conditions. Treatments are delivered by qualified physicians and address major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes. Patients access care through free phone consultations, online contact forms, and provider referrals, and pay per treatment session at their preferred clinic location.
Product overview
Actify Neurotherapies offers a single core service: Ketamine Infusion Therapy. The company operates a network of 10+ treatment centers across the United States providing intravenous ketamine treatments for treatment-resistant mental health conditions. The therapy is positioned as an alternative to daily medications for patients who have not responded to traditional treatments. The company facilitates initial consultations, coordinates treatment scheduling across locations, and provides ongoing care through its network of medical doctors.
Differentiator
Problem solved
Functional benefit
Products and services
- Ketamine Infusion Therapy
Quantifiable outcome
- Rapid symptom relief within hours of treatment (vs. weeks for traditional antidepressants)
- +1 more outcomes
Companies that use Actify Neurotherapies
Customer profileSegments6 records
Ideal customer profiles1 record
Actify Neurotherapies technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Actify Neurotherapies partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights4 records
Actify Neurotherapies competitors and assessment
Company assessmentBroad incumbents
- Cerebral: Large digital mental health platform offering medication management and therapy for depression and anxiety. Comparable in target patient demographic and mental-health focus, but operates via telehealth and prescription rather than in-clinic infusion.
- Spravato (Janssen / Johnson & Johnson): FDA-approved esketamine nasal spray for treatment-resistant depression, marketed by Janssen. The principal pharmaceutical incumbent addressing Actify's core depression patient population through a regulated, insurance-covered alternative that competes for the same clinical use case.
Direct peers
- Nue Life: Ketamine therapy provider combining infusion clinics with at-home treatment programs for depression, PTSD, and anxiety. Directly comparable to Actify in indication set and patient demographic, with overlapping emphasis on treatment-resistant populations.
- Ketamine Wellness Centers: National network of ketamine infusion clinics treating depression, PTSD, anxiety, and chronic pain. Direct comparable in clinic-network model, multi-condition offering, and geographic distribution strategy.
- Klarity Clinic: Specialty outpatient clinic offering ketamine and Spravato infusions for depression, anxiety, and PTSD. Closely comparable in service mix, multi-condition scope, and direct-to-consumer patient acquisition.
- Better U: Outpatient ketamine and Spravato clinic operator serving treatment-resistant mental health patients. Comparable in service offering and patient target, though typically with smaller clinic footprints than Actify.
- Field Trip Health: Was a direct competitor operating ketamine-assisted psychotherapy clinics in major US and Canadian cities before winding down US clinic operations. Operated the same multi-clinic, ketamine-for-mental-health model as Actify and remains the closest precedent for clinic-network scaling in this category.
- Journey Clinical: Telehealth-enabled platform connecting patients with clinicians providing ketamine and Spravato treatment. Comparable patient population and treatment offerings, differing in delivery modality (remote prescriber network vs. owned clinics).
- Mindbloom: Direct competitor offering ketamine therapy for mental health conditions. While Mindbloom emphasizes at-home sublingual ketamine versus Actify's in-clinic IV, both target the same treatment-resistant patient population with the same active drug and similar outcome messaging.
Emerging players
- Spring Health: Employer-sponsored mental health platform providing therapy, medication, and care navigation. Targets a similar mental-health patient population but through a virtual-first, benefits-funded model rather than clinic-based ketamine infusion.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
Actify Neurotherapies social profiles
Digital presenceActify Neurotherapies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Actify Neurotherapies leadership team
Management profileNumber of profiles
Profiles17 records
Actify Neurotherapies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Actify Neurotherapies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Actify Neurotherapies
What does Actify Neurotherapies do?
Actify Neurotherapies operates a network of 10 ketamine infusion therapy centers across the United States that administer intravenous ketamine treatments to patients with treatment-resistant mental health conditions. Treatments are delivered by qualified physicians and address major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes. Patients access care through free phone consultations, online contact forms, and provider referrals, and pay per treatment session at their preferred clinic location.
Is Actify Neurotherapies a public or private company?
Actify Neurotherapies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Actify Neurotherapies founded?
Actify Neurotherapies was founded in 2011. It employs 11 to 50 people.
Where is Actify Neurotherapies based?
Actify Neurotherapies is headquartered in Princeton, United States, in the North America region.
How does Actify Neurotherapies make money?
One revenue line is on record: ketamine Infusion Treatment Services.
Who are Actify Neurotherapies's main competitors?
Broad incumbents on record are Cerebral and Spravato (Janssen / Johnson & Johnson). Direct peers are Nue Life, Ketamine Wellness Centers, Klarity Clinic, Better U, Field Trip Health, Journey Clinical and Mindbloom. Spring Health is listed as an emerging player.
Does Actify Neurotherapies have an API?
No public API is recorded for Actify Neurotherapies.
What industry is Actify Neurotherapies in?
Actify Neurotherapies's product category is Mental Health Infusion Services. Its primary akta.pro industry code is HLAFACAG, Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 62142 and its SIC code is 8093.